What is Beam Therapeutics's operating cash flow?

Beam Therapeutics (BEAM) reported operating cash flow of -$128.51M in Q1 2026.

How has Beam Therapeutics's operating cash flow changed year-over-year?

Beam Therapeutics's operating cash flow decreased by 23.7% year-over-year, from -$103.88M to -$128.51M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Beam Therapeutics BEAM Operating Cash Flow

Operating Cash Flow at other companies

Vertex PharmaceuticalsVRTX

$1.43B+74.4%

Arrowhead ResearchARWR

$84.44M-81.6%

CRISPR TherapeuticsCRSP

-$108.9M-102%

Cogent Biosciences, Inc.COGT

-$86.88M-30.6%

PTC TherapeuticsPTCT

-$59.04M-107%

BridgeBio PharmaBBIO

-$197.28M+1.0%

Other financials

Income statement

See full

Revenue$31.7M+325%

Operating income-$107.2M+10.1%

Net income-$94.3M+12.9%

EPS (diluted)-$0.91+26.0%

Balance sheet

See full

Cash & equivalents$288.3M-45.4%

Total debt$250.8M+58.6%

Total equity$1.2B+3.1%

Total assets$1.5B+0.9%

Cash flow

See full

CapEx$2.2M-27.2%

Free cash flow-$130.7M-22.2%

Valuation

See full

Market cap$3.51B+24.5%

Enterprise value$3.47B+51.2%

P/S21.4×-23.0×

Profitability

See full

Operating margin-226.6%-90.5pp

Net margin-742.7%—

FCF margin-234%-86.6pp

Returns & leverage

See full

Return on equity-47.1%—

Debt / equity0.2×+0.1×

Current ratio17×+8.2×

Where this comes from

Reported directly by Beam Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Beam Therapeutics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Beam Therapeutics's operating cash flow?: Beam Therapeutics (BEAM) reported operating cash flow of -$128.51M in Q1 2026.
How has Beam Therapeutics's operating cash flow changed year-over-year?: Beam Therapeutics's operating cash flow decreased by 23.7% year-over-year, from -$103.88M to -$128.51M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.